| |
| |
Have you checked out the INATE website?
INATE (INvestigators Against ThromboEmbolism) is an educational website that aims to improve the worldwide management of patients with venous thromboembolism (VTE). Started in 2001 by a Core Group of 12 investigators from various disciplines around the globe, it is an excellent source of information for both patients and professionals.
|
| |
|
|
|
| |
Content for site developed under the guidance of the TRACK Advisory Council.
|
|
 |
|
| |
 |
|
|
|
| |
Expert Commentary |
| |
|
| |
Expert Commentary offers you the latest interviews with key opinion leaders
|
|
|
|
|
| |
Selecting an Antithrombotic Therapy for the NSTEMI Patient
In this Expert Commentary, Paul Ruest PhD interviews Dr Robert Giugliano regarding the process and choices associated with selecting an antithrombotic therapy for the patient with non-ST elevation acute coronary syndrome (NSTE-ACS). Dr Giugliano will describe in detail the evidence supporting guideline recommendations and discuss risk stratification, available agents, and the rationale behind selecting these agents for treating this patient population.
Read full commentary
|
|
| |
| |
Risk Stratification for Venous Thromboembolism
While there is no universally accepted method for stratifying venous thromboembolism (VTE) risk for medical or surgical patients, Dr Arthur Wheeler discusses various strategies in this Expert Commentary. Dr Wheeler also discusses the barriers to VTE risk stratification and provides unique insight into ways to overcome these barriers. Dr Wheeler summarizes recent landmark deep vein thrombosis (DVT) prophylaxis clinical trials and the impact they may have on managing patients who must be correctly assessed for risk before the appropriate treatment can be given.
Read full commentary
|
|
| |
| |
Meeting New Performance Measures and Identifying Barriers to Thromboprophylaxis
In this Expert Commentary, Dr Geno Merli addresses the barriers to the implementation of thromboprophylaxis in medically ill patients and explains the benefits of thromboprophylaxis in reducing the morbidity and mortality associated with venous thromboembolism in these patients. Dr Merli discusses the results of recent clinical trials and registries that address thromboprophylactic measures and the impact they have on current clinical practice. Through a careful dissection of the implementation of performance measure programs for VTE treatment and prophylaxis, Dr Merli provides insight as to the effectiveness of these programs in achieving their goal of improved quality of care for medical and surgical patients who are either at risk for or who have venous thromboembolic disease.
Read full commentary
|
|
| |
| |
Aspirin Resistance in Thrombosis Management
In this expert commentary, Deepak L. Bhatt, MD, Director of the Interventional Cardiovascular Fellowship at the Cleveland Clinic Foundation in Cleveland, Ohio, discusses the current data available on aspirin resistance and emerging insights on how these data should influence clinical decision-making.
Read full commentary
|
|
| |
| |
Reducing Door-to-Treatment Times and Meeting New Performance Measures in Acute Coronary Syndromes
In this Expert Commentary, Dr Marc Cohen addresses various strategies for reducing the interval between arrival at the hospital and intracoronary balloon inflation during primary percutaneous coronary intervention, as well as reducing the interval between arrival at the hospital and administration of thrombolytic agents. Dr Cohen also addresses barriers associated with these goals and discusses new performance measures in acute coronary syndromes.
Read full commentary
|
|
| |
| |
Upcoming Trials in VTE
In this expert commentary, Dr Kakkar provides a detailed overview of recent clinical trials that will have an impact on preventing VTE in certain patient populations
Read full commentary
|
|
| |
| |
Antithrombotic Therapy in the PCI Patient
In this expert commentary Dr Levine talks about various treatment options for patients who present with ACS based on risk stratification and also describes the rationale for selection of an optimal therapeutic regimen that includes antiplatelet and antithrombin agents. He also discusses the impact of recent clinical trials on treatment options and evaluates current practice standards to determine guideline accordance.
Read full commentary
|
|
| |
| |
Management of Bleeding Complications
Bleeding is the most common complication associated with antithrombotic agents. Bleeding severity may range from mild, or “nuisance” bleeding, to serious, life-threatening hemorrhage. In this expert commentary, Ann Wittkowsky, PharmD, discusses the risk factors for bleeding, as well as the different methods for categorizing bleeding used in clinical trials and in practice.
Read full commentary
|
|
| |
| |
Recent Trials on Anticoagulation in Patients With ST-elevation Myocardial Infarction
Cardiovascular disease is the leading cause of death in the United States, and 1.4 million Americans are expected to have myocardial infarctions this year. In this Expert Commentary, Dr Marc Cohen will review the results of 2 large clinical trials on patients with ST-elevation myocardial infarction (STEMI) and discuss the implications for patient care.
Read full commentary
|
|
| |
| |
Antithrombotic Therapy Considerations in Special Patient Populations
In this two part expert commentary, Dr Edith A. Nutescu discusses antithrombotic therapy considerations relevant to obese patients and patients with impaired renal function.
Read full commentary
|
|
| |
| |
Orthopedic Thromboprophylaxis: The Timing of Administration
In this expert commentary, Dr Warwick discusses the timing of VTE prophylaxis administration for orthopedic surgeries. He discusses the numerous implications that are associated with assessing a patient’s risk for developing thrombosis after surgery.
Read full commentary
|
|
| |
| |
Secondary Prevention of VTE in Acute Ischemic Stroke Patients
In this expert commentary, Dr Sherman gives an overview on how to prevent VTE in acute ischemic stroke patients. He addresses the incidence of VTE (manifested as DVT or PE) as a complication of acute ischemic stroke and the possible outcomes of this complication.
Read full commentary
|
|
| |
| |
Pharmacoeconomics of Low-molecular-weight Heparin Versus Unfractionated Heparin
In this expert commentary, Prof Lee Vermeulen discusses the economic benefits of using thromboprophylaxis in acutely ill medical patients.
Read full commentary
|
|
| |
| |
The Design of Clinical Trials
In this expert commentary, Dr Marc Cohen answers questions on the design and execution of clinical trials. He discusses the different kinds of clinical trials and the advantages and disadvantages of each type.
Read full commentary
|
|
| |
| |
Anticoagulation Issues in Atrial Fibrillation
In this expert commentary, Dr Hirsh will discuss the incidence and risks associated with AF, list high-risk characteristics of AF patients (eg, patient age, congestive heart failure, diabetes), major potential food and drug interactions of warfarin and their clinical significance. He will also compare and contrast the key clinical differences between unfractionated heparin, LMWH, ximelagatran, aspirin, and warfarin when used in AF anticoagulant strategies.
Read full commentary
|
|
| |
| |
Patient Registries
In this expert commentary, Dr Eagle describes the types of information that can be derived from patient registries, such as the adoption of new technology or practice guidelines.
Read full commentary
|
|
| |
| |
Duration of Prophylaxis in Medical Patients
In this expert commentary, Dr Victor F. Tapson describes the types of medical patients studied in VTE clinical trials and the variety of pharmacological and nonpharmacological options available for prophylaxis of VTE. He discusses the risks and benefits associated with each option, including heparin, low-molecular-weight heparin, warfarin, fondaparinux, ximelagatran, and mechanical methods of prophylaxis.
Read full commentary
|
|
| |
| |
Identifying Patients with DVT or PE: Current Standards and Future Directions
In this expert commentary, Dr Amir Jaffer discusses current standards and future directions with regard to diagnosis of patients with DVT or PE. VTE is the 3rd leading cause of cardiovascular death in the United States, with an estimated 2 million cases of DVT occurring every single year.
Read full commentary
|
|
| |
| |
Interview with Joseph A. Caprini, MD
In this expert commentary, Dr Caprini discusses the guidelines based on The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Prophylaxis for Venous Thromboembolism.
Read full commentary
|
|
| |
| |
Interview with Jonathan L. Halperin, MD
In this interview, Dr Jonathan Halperin addresses key issues surrounding ximelagatran clinical trials and the decision by the Food and Drug Administration (FDA) not to grant new drug application (NDA) approval.
Read full commentary
|
|
| |
| |
Interview with Kenneth W. Mahaffey, MD
The following program, including a trial synopsis and expert commentary by Dr Kenneth Mahaffey, provides an overview of the key findings of SYNERGY and insight into their potential impact on current clinical practice.
Read full commentary
|
|
| |
|
| |
|
|
| |
|
|